{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:42:35Z","timestamp":1793824955663,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eprac.2020.09.016","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T13:44:08Z","timestamp":1609422248000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary\u00a0Adrenal Insufficiency: Systematic Review and Optimal Management"],"prefix":"10.1016","volume":"27","author":[{"given":"Yun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2020.09.016_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI131194","article-title":"Time to dissect the autoimmune etiology of cancer antibody immunotherapy","volume":"130","author":"Dougan","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.016_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eprac.2020.09.016_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.016_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nature Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2020.09.016_bib5","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.016_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.016_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eprac.2020.09.016_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.016_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000491631","article-title":"Acute kidney injury after pembrolizumab-induced adrenalitis and adrenal insufficiency","volume":"8","author":"Hanna","year":"2018","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.eprac.2020.09.016_bib10","article-title":"Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer","author":"Agrawal","year":"2019","journal-title":"Case Rep Neurol Med"},{"issue":"2","key":"10.1016\/j.eprac.2020.09.016_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","article-title":"Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer","volume":"47","author":"Kagoshima","year":"2020","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.016_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2020.09.016_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tjem.2017.05.007","article-title":"Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis","volume":"17","author":"Akarca","year":"2017","journal-title":"Turk J Emerg Med"},{"issue":"11","key":"10.1016\/j.eprac.2020.09.016_bib14","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.eprac.2020.09.016_bib15","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2020.09.016_bib16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.eprac.2020.09.016_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison's disease: a rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.016_bib18","first-page":"16","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.eprac.2020.09.016_bib19","first-page":"526","article-title":"Avelumab inducing hypothyroidism and hypoadrenalism: a case report and review of literature","volume":"17","author":"Aziz","year":"2018","journal-title":"EXCLI J"},{"issue":"1","key":"10.1016\/j.eprac.2020.09.016_bib20","first-page":"1","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.eprac.2020.09.016_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","volume":"79","author":"Haissaguerre","year":"2018","journal-title":"Annales D'endocrinologie"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:16Z","timestamp":1761516556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20483995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1530891X20483995"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2020.09.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary\u00a0Adrenal Insufficiency: Systematic Review and Optimal Management","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2020.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}